PubMed=9741429; DOI=10.1089/hum.1998.9.13-1909
Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J.M., Hehir K.M., Keegan J., Auger C., Cramer S.J., van Ormondt H., van der Eb A.J., Valerio D., Hoeben R.C.
New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.
Hum. Gene Ther. 9:1909-1917(1998)

PubMed=11257414; DOI=10.1016/S0264-410X(00)00508-9
Pau M.G., Ophorst C., Koldijk M.H., Schouten G.J., Mehtali M., Uytdehaag F.G.C.M.
The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.
Vaccine 19:2716-2721(2001)

Patent=US6602706
Fallaux F.J., Hoeben R.C., van der Eb A.J., Bout A., Valerio D.
Packaging systems for human recombinant adenovirus to be used in gene therapy.
Patent number US6602706, 05-Aug-2003

PubMed=16566444
Lewis J.A., Brown E.L., Duncan P.A.
Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines.
Dev. Biol. (Basel) 123:165-176(2006)

PubMed=18052336; DOI=10.1021/bp070258u
Berdichevsky M., Gentile M.-P., Hughes B., Meis P., Peltier J., Blumentals I., Aunins J., Altaras N.E.
Establishment of higher passage PER.C6 cells for adenovirus manufacture.
Biotechnol. Prog. 24:158-165(2008)

PubMed=25903999; DOI=10.1002/biot.201400388
Genzel Y.
Designing cell lines for viral vaccine production: where do we stand?
Biotechnol. J. 10:728-740(2015)

Patent=US9469865
Zijlstra G.M., Hof R.P., Schilder J.
Process for the culturing of cells.
Patent number US9469865, 18-Oct-2016

PubMed=28450423; DOI=10.1530/EC-17-0067; PMCID=PMC5510450
Koechling W., Plaksin D., Croston G.E., Jeppesen J.V., Macklon K.T., Andersen C.Y.
Comparative pharmacology of a new recombinant FSH expressed by a human cell line.
Endocr. Connect. 6:297-305(2017)